Novo Nordisk A/S Common Stock (NY:NVO)

37.32 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗

December 31, 2025

Via MarketBeat

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Why Novo Nordisk Stock Dropped on Monday ↗

December 30, 2025

The cost of Wegovy is about to decrease significantly in a populous overseas market.

Via The Motley Fool

Topics Intellectual Property

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Topics ETFs Economy World Trade

The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance

December 29, 2025

As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

December 29, 2025

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Via PredictStreet

Topics Earnings Economy Intellectual Property

Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset

December 29, 2025

As the final trading days of 2025 approach, the relentless momentum that propelled major U.S. indices to historic heights has entered a period of measured consolidation. After a year defined by the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗

December 29, 2025

Is this the start of a sustained run for the Danish drugmaker?

Via The Motley Fool

Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗

December 29, 2025

Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai.

Via Stocktwits

Topics Intellectual Property

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗

December 29, 2025

Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.

Via The Motley Fool

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Via The Motley Fool

Topics Intellectual Property

Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗

December 26, 2025

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Via The Motley Fool

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗

December 26, 2025

Via MarketBeat

This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗

December 26, 2025

The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025.

Via Stocktwits

Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗

December 26, 2025

A key product portfolio is bringing in blockbuster revenue.

Via The Motley Fool

Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close

December 25, 2025

As the sun sets on 2025, the U.S. stock market is not entering the quiet holiday lull typical of decades past. Instead, a massive surge in "unusual options activity" is signaling a high-stakes...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗

December 25, 2025

It's a two-horse race right now, sort of.

Via The Motley Fool

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

Via MarketMinute

Topics Economy Intellectual Property

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Via PredictStreet

Topics Economy Intellectual Property World Trade

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Via PredictStreet

Topics Economy Government Intellectual Property

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Via PredictStreet

Topics Economy

Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook

December 24, 2025

As of December 24, 2025, the pharmaceutical landscape is witnessing a pivotal shift in the treatment of chronic obesity. Novo Nordisk (NYSE: NVO), the Danish titan that pioneered the GLP-1 revolution,...

Via PredictStreet

Topics Economy Intellectual Property

Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗

December 24, 2025

Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

Via Stocktwits

Novo Nordisk A/S-Spons ADR (NYSE:NVO): A Prime Candidate for Steady Dividend Income ↗

December 24, 2025

Novo Nordisk (NVO) exemplifies a strong dividend stock with a 3.83% yield, a history of increases, and robust profitability for sustainable passive income.

Via Chartmill

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.